Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Antistaphylococcal activity of a cyclic peptide, LY146032, and vancomycin.

Literature DB >> 3028254

Antistaphylococcal activity of a cyclic peptide, LY146032, and vancomycin.

Abstract

The inhibitory and bactericidal activities of a novel cyclic peptide antibiotic, LY146032, and vancomycin against oxacillin-susceptible and oxacillin-resistant staphylococci were compared. The MICs for 90% of strains were two- to fourfold higher for vancomycin than for LY146032. MBC/MIC ratios for all strains were less than or equal to 2. In killing rate studies with four strains of staphylococci, there was no detectable growth in the presence of 4X the MIC of either LY146032 or vancomycin after 24 h of incubation.

Entities: Chemical Disease

Mesh：

Substances：

Year: 1986 PMID： 3028254 PMCID： PMC180623 DOI： 10.1128/AAC.30.6.938

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

1 in total

1. MBCs for Staphylococcus aureus as determined by macrodilution and microdilution techniques.

Authors: C J Shanholtzer; L R Peterson; M L Mohn; J A Moody; D N Gerding
Journal: Antimicrob Agents Chemother Date: 1984-08 Impact factor: 5.191

1 in total

11 in total

1. Treatment of chronic experimental Staphylococcus aureus osteomyelitis with LY146032 and vancomycin.

Authors: Q N Luu; T B Buxton; D R Nelson; J P Rissing
Journal: Eur J Clin Microbiol Infect Dis Date: 1989-06 Impact factor: 3.267

2. Antimicrobial activity and spectrum of LY146032, a lipopeptide antibiotic, including susceptibility testing recommendations.

Authors: R N Jones; A L Barry
Journal: Antimicrob Agents Chemother Date: 1987-04 Impact factor: 5.191

3. Activity of LY146032 compared with that of methicillin, cefazolin, cefamandole, cefuroxime, ciprofloxacin, and vancomycin against staphylococci as determined by kill-kinetic studies.

Authors: C W Stratton; C Liu; L S Weeks
Journal: Antimicrob Agents Chemother Date: 1987-08 Impact factor: 5.191

Review 4. Methicillin-resistant staphylococci: detection methods and treatment of infections.

Authors: C J Hackbarth; H F Chambers
Journal: Antimicrob Agents Chemother Date: 1989-07 Impact factor: 5.191

5. Roadmap for antibiotic discovery.

Authors: Carolyn K Shore; Allan Coukell
Journal: Nat Microbiol Date: 2016-05-26 Impact factor: 17.745

Review 6. Methicillin-resistant staphylococci.

Authors: H F Chambers
Journal: Clin Microbiol Rev Date: 1988-04 Impact factor: 26.132

Antistaphylococcal activity of a cyclic peptide, LY146032, and vancomycin.

1. MBCs for Staphylococcus aureus as determined by macrodilution and microdilution techniques.

1. Treatment of chronic experimental Staphylococcus aureus osteomyelitis with LY146032 and vancomycin.

2. Antimicrobial activity and spectrum of LY146032, a lipopeptide antibiotic, including susceptibility testing recommendations.

3. Activity of LY146032 compared with that of methicillin, cefazolin, cefamandole, cefuroxime, ciprofloxacin, and vancomycin against staphylococci as determined by kill-kinetic studies.

Review 4. Methicillin-resistant staphylococci: detection methods and treatment of infections.

5. Roadmap for antibiotic discovery.

Review 6. Methicillin-resistant staphylococci.

7. In vitro activities of daptomycin (LY146032) and paldimycin (U-70,138F) against anaerobic gram-positive bacteria.

8. Lipoteichoic acid as a new target for activity of antibiotics: mode of action of daptomycin (LY146032).

9. In vitro selection of bacteria resistant to LY146032, a new cyclic lipopeptide.

10. In vivo pharmacodynamic activity of daptomycin.